Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: A prospective randomised trial in China

European Journal of Cancer

Volumn 50, Issue 10, 2014, Pages 1772-1778

  Du, Chun Yan ^a,b   Zhou, Ye ^a,b   Song, Chun ^c   Wang, Yong Peng ^c   Jie, Zhi Gang ^d   He, Yu Long ^e   Liang, Xiao Bo ^f   Cao, Hui ^g   Yan, Zhong Shu ^h   Shi, Ying Qiang ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c LIAONING CANCER HOSPITAL AND INSTITUTE   (China)

^d NANCHANG UNIVERSITY   (China)

^e SUN YAT SEN UNIVERSITY   (China)

^f SHANXI CANCER HOSPITAL   (China)

^g SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^h CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Gastrointestinal stromal tumours; Imatinib mesylate; Surgery

Indexed keywords

IMATINIB;

ADULT; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHINA; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LIVER METASTASIS; MALE; MINIMAL RESIDUAL DISEASE; MOLECULARLY TARGETED THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR VOLUME;

GASTROINTESTINAL STROMAL TUMOURS; IMATINIB MESYLATE; SURGERY;

ANTINEOPLASTIC AGENTS; BENZAMIDES; CHEMOTHERAPY, ADJUVANT; CHINA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; METASTASECTOMY; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PATIENT SELECTION; PIPERAZINES; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SAMPLE SIZE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84901754499     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.03.280     Document Type: Article

References (23)

1. R.P. DeMatteo, J.J. Lewis, D. Leung, S.S. Mudan, J.M. Woodruff, and M.F. Brennan Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival Ann Surg 231 2000 51 58
2. R.P. Dematteo, M.C. Heinrich, W.M. El-Rifai, and G. Demetri Clinical management of gastrointestinal stromal tumors: before and after STI-571 Hum Pathol 33 2002 466 477
3. C.D. Blanke, C. Rankin, and G.D. Demetri et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033 J Clin Oncol 26 2008 626 632
4. M. Van Glabbeke, J. Verweij, and P.G. Casali et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organization for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study J Clin Oncol 23 2005 5795 5804
5. M. Von Mehren Imatinib-refractory gastrointestinal stromal tumors: the clinical problem and therapeutic strategies Curr Oncol Rep 8 2006 192 197
6. C.R. Antonescu, P. Besmer, and T. Guo et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation Clin Cancer Res 11 2005 4182 4190
7. C.L. Corless, J.A. Fletcher, and M.C. Heinrich Biology of gastrointestinal stromal tumors J Clin Oncol 22 2004 3813 3825
8. S. Bonvalot, H. Eldweny, and C.L. Péchoux et al. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era Ann Surg Oncol 13 2006 1596 1603
9. S. Bauer, J.T. Hartmann, and M. de Wit et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib Int J Cancer 117 2005 316 325
10. E. Wardelmann, N. Thomas, and S. Merkelbach-Bruse et al. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations Lancet Oncol 6 2005 249 251
11. M.C. Herinrich, C.L. Corless, and C.D. Blanke et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors J Clin Oncol 24 2006 4764 4774
12. P. Bumming, J. Andersson, and J.M. Meis-Kindblom et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients Br J Cancer 89 2003 460 464
13. J.S. Gold, and R.P. DeMatteo Neoadjuvant therapy for gastrointestinal stromal tumor (GIST): racing against resistance Ann Surg Oncol 14 2007 1247 1248
14. A. Gronchi, M. Fiore, and F. Miselli et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST Ann Surg 245 2007 341 346
15. C.N. Yeh, T.W. Chen, and J.H. Tseng et al. Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment J Surg Oncol 102 2010 599 603
16. C.L. Scaife, K.K. Hunt, and S.R. Patel et al. Is there a role for surgery in patients with 'unresectable' cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? Am J Surg 186 2003 665 669
17. R.H. Andtbacka, C.S. Ng, and C.L. Scaife et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib Ann Surg Oncol 14 2007 14 24
18. R. Cirocchi, E. Farinella, and F. La Mura et al. Efficacy of surgery and imatinib mesylate in the treatment of advanced gastrointestinal stromal tumor: a systematic review Tumori 96 2010 392 399
19. R.P. DeMatteo, R.G. Maki, S. Singer, M. Gonen, M.F. Brennan, and C.R. Antonescu Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor Ann Surg 245 2007 347 352
20. C.P. Raut, M. Posner, and J. Desai et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors J Clin Oncol 24 2006 2325 2331
21. D. Wang, Q. Zhang, and C.D. Blanke et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable GIST: long-term follow-up results of RTOG 0132 Ann Surg Oncol 19 2012 1074 1080
22. L. Xia, M.M. Zhang, and L. Ji et al. Resection combined with imatinib therapy for liver metastases of gastrointestinal stromal tumors Surg Today 40 2010 936 942
23. S. Bauer, P. Rutkowski, and P. Hohenberger et al. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib - analysis of prognostic factors (EORTC-STBSG collaborative study) Eur J Surg Oncol 40 2014 412 419